Search Results

You are looking at 111 - 120 of 151 items for :

  • "renal cell carcinoma" x
Clear All
Full access

Justin A. Chen, Naseem Esteghamat, Edward J. Kim, Gabriel Garcia, Jun Gong, Marwan G. Fakih, Richard J. Bold and May T. Cho

impairment was due to cirrhosis from alcohol ingestion or hepatitis and metastatic disease. Primary neoplasms in these patients included Hodgkin lymphoma, 29 melanoma, renal cell carcinoma, small cell and non–small lung cancers, and urothelial carcinoma, 28

Full access

Jarushka Naidoo, Jiajia Zhang, Evan J. Lipson, Patrick M. Forde, Karthik Suresh, Kendall F. Moseley, Seema Mehta, Shawn G. Kwatra, Alyssa M. Parian, Amy K. Kim, John C. Probasco, Rosanne Rouf, Jennifer E. Thorne, Satish Shanbhag, Joanne Riemer, Ami A. Shah, Drew M. Pardoll, Clifton O. Bingham III, Julie R. Brahmer and Laura C. Cappelli

advanced renal-cell carcinoma . N Engl J Med 2018 ; 378 : 1277 – 1290 . 29562145 10.1056/NEJMoa1712126 14. Antonia SJ , López-Martin JA , Bendell J , . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate

Full access

Emily H. Castellanos, Sheau-chiann Chen, Hillary Drexler and Leora Horn

. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies . Oncologist 2011 ; 16 ( Suppl 2 ): 32 – 44 . 3. Cataldo VD Gibbons DL Perez-Soler R Quintas-Cardama A . Treatment of

Full access

Marjorie G. Zauderer and Lee M. Krug

multidrug immunosuppression regimen in solid organ transplantation, and has also been approved for the treatment of advanced renal cell carcinoma after sunitinib or sorafenib. SWOG is conducting a phase II trial of everolimus in patients with MPM who were

Full access

chemotherapy in early-stage BC. Outcomes and Health Services Research AB2015-12. Comparing Costs and Health Outcomes in Initial Therapy With Sunitinib Versus Pazopanib for Renal Cell Carcinoma Patrick Racsa, MS a ; Karen Worley, PhD a ; and Tyler

Full access

Van K. Morris and Cathy Eng

. Nivolumab versus everolimus in advanced renal-cell carcinoma . N Engl J Med 2015 ; 373 : 1803 – 1813 . 24. Garon EB Rizvi NA Hui R . Pembrolizumab for the treatment of non-small-cell lung cancer . N Engl J Med 2015 ; 372 : 2018 – 2028

Full access

Elio Mazzone, Sophie Knipper, Francesco A. Mistretta, Carlotta Palumbo, Zhe Tian, Andrea Gallina, Derya Tilki, Shahrokh F. Shariat, Francesco Montorsi, Fred Saad, Alberto Briganti and Pierre I. Karakiewicz

S , Preisser F , . Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma . Cancer Epidemiol 2018 ; 56 : 118 – 125 . 10.1016/j.canep.2018.08.006 26. Abdollah F , Sammon

Full access

Scott F. Huntington, Jessica R. Hoag, Rong Wang, Amer M. Zeidan, Smith Giri, Steven D. Gore, Xiaomei Ma, Cary P. Gross and Amy J. Davidoff

-010): a randomised controlled trial . Lancet 2016 ; 387 : 1540 – 1550 . 10.1016/S0140-6736(15)01281-7 26712084 3. McDermott DF , Sosman JA , Sznol M , . Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell

Full access

Jilma Patrick and Seema Ahsan Khan

the primary tumor. These studies include a randomized trial of patients with stage IV renal cell carcinoma that demonstrated a modest but significant survival advantage for the nephrectomy group. 3 Improved survival with resection of primary disease

Full access

John A. Charlson, Emily L. McGinley, Ann B. Nattinger, Joan M. Neuner and Liliana E. Pezzin

the fact that several malignancies, such as chronic myeloid leukemia (CML) and renal cell carcinoma, have multiple oral treatment options available, our study provides an analytical framework that is applicable to other situations. This article